MDS Virtual Congress 2021 Archives - Page 75 of 132

CAN DANCE AS A COMPLEMENTARY THERAPY REDUCE THE OCCURRENCE OF DEPRESSION AND APATHY IN PEOPLE WITH PARKINSON’S DISEASE?

I. Machado, L. Fontes, B. Dos Santos-Lobato, L. Krejcova (Belém, Brazil)
Can event-related oscillations aid in differentiating Parkinson’s disease and dementia with Lewy bodies?

Y. Rosenblum, T. Shiner, N. Bregman, I. Maidan, F. Fahoum, N. Giladi, A. Mirelman (Tel Aviv, Israel)
Can reduced attention or visuoexecutive functioning predict perceived walking difficulties in people with Parkinson’s disease (PD)?

M. Lindh-Rengifo, S. Jonasson, N. Mattsson-Carlgren, M. Nilsson (Lund, Sweden)
Can telehealth support people with Parkinson’s disease to exercise at home?

A. Flynn, C. Canning, E. Preston, S. Dennis, N. Allen (Bruce, Australia)
Can we predict the development of REM sleep behavior disorder (RBD) in military veterans with Parkinson’s disease?

A. Sarwar (Houston, USA)
Carboplatin, Paclitaxel, and Nivolumab-induced Parkinsonism Responsive to Levodopa

M. Branston, O. Tong (Sacramento, USA)
Cardiovascular risk factors and phenoconversion to neurodegenerative synucleinopathies in idiopathic REM sleep behavior disorder

N. Lewandowski, S. Zolfaghari, A. Pelletier, S A. Naeimi, J-F. Gagnon, M. Brillon-Corbeil, J. Montplaisir, R. Postuma (Montreal, Canada)
Care Partners in Parkinson’s: Who calls the Parkinson’s Foundation Helpline and why?

A. Hedges, S. Metz, A. Diaz, L. Pituch, J. Mcclure, D. Ojeda, C. Mckee, A. Janicke, T. Via, M. Feeney (Miami, USA)
Caregiver burden in patients with Parkinson disease

S. Tomic, J. Kragujevic, Z. Popijac, V. Pekic (Osijek, Croatia)
Caregivers’ Experiences and Coping Mechanisms in Caring for Persons with Parkinson’s Disease: A Ghanaian Support Group Meeting Report

M. Agoriwo, B. Atsivor, E. Djzokoto (Ho, Ghana)
Caregiving in Parkinson’s Disease: An International Perspective

E. Book, R. Dawson, A. Allen, L. Kapust, J. Mckenzie, M. Ueda, A. Yu (Vancouver, Canada)
Caregiving people with Parkinson’s disease (PPD)

M. Bacigalupe (La Plata, Argentina)
Case of Chorea Hyperglycemia Basal Ganglia syndrome with normal glucose

M. Wangsuwana (Las Vegas, USA)
Causes of deaths in patients with Parkinson’s disease in the era before the use of modern drug therapy and at the present time

S. Shtaimets (Omsk, Russian Federation)
Celiac disease-related antibodies in Parkinson’s Disease patients: a case control study.

GUL. şahbaz, BOB. Barut, SDT. Tekol (Istanbul, Turkey)
Cellular Modeling of Tyrosine Hydroxylase Deficiency Recapitulates Patient Phenotypes and Response to Treatment.

A. Tristán-Noguero, I. Fernández-Carassa, C. Bermejo-Casadesús, C. Calatayud, L. Campa, F. Artigas, R. Domingo-Jiménez, M. Pineda, S. Alcántara, A. Raya, R. Artuch, A. García-Cazorla, A. Consiglio (Esplugues de Llobregat, Spain)
Central and Peripheral neurological manifestations of COVID-19 in a cohort of patients with Parkinson’s disease.

A. Vaish, B. Tyson, S. Ray (Redmond, USA)
Central pain in Parkinson’s disease

M. Elfekih, I. Bedoui, B. Douma, M. Mansour, H. Derbali, A. Riahi, M. Messelmani, J. Zaouali, R. Mrissa (Nabeul, Tunisia)
Central Pontine Myelinolysis Related Tremor Effectively Treated With Deep Brain Stimulation

D. Machado, A. Kelly (Cheshire, USA)
Cerebellar atrophy secondary to lithium intoxication : about 2 cases

M. Fall (Dakar, Senegal)
Cerebellar bioenergetic depletion following ubiquinol supplementation in a patient with COQ8A-related ataxia

J. Prasuhn, M. Göttlich, B. Ebeling, C. Bodemann, S. Großer, I. Wellach, K. Reuther, H. Hanssen, N. Brüggemann (Lübeck, Germany)
CEREBELLAR COGNITIVE AFFECTIVE SYNDROME IN SPINOCEREBELLAR ATAXIA TYPE 3

KH. Yap, S. Azmin, SH. Mat Desa, HN. Achok, N. Mohamed Ibrahim (Cheras, Malaysia)
Cerebellar Pathway Outflow Tremor from Thalamic and Midbrain Glioma Responded to Dopaminergic Therapy

K. Yen, A. Yaworski, M. Bussiere, F. Ba (Edmonton, Canada)
Cerebellar tDCS for multiple system atrophy cerebellar: Double blinded, randomized, sham-control, cross-over study

JH. Ahn, J. Song, I. Choi, DY. Lee, JW. Cho, WH. Chang, J. Youn (Seoul, Republic of Korea)
Cerebral white matter atrophy may be associated with the performance of activities of daily livings in patients with Parkinson’s disease

YK. Chen, ZH. Lu, XL. Fu (Dongguan, China)
Cerebrospinal fluid levels of oxidative stress measured using diacron-reactive oxygen metabolites and biological antioxidant potential in patients with Parkinson’s disease and progressive supranuclear palsy

K. Takahashi, K. Iwaoka, K. Takahashi, Y. Suzuki, K. Taguchi, K. Yamahara, T. Maeda (Yahaba, Shiwa, Iwate, Japan)
Challenges around end-of-life care for people with Parkinson’s disease in Kenya

N. Fothergill-Misbah, J. Hooker, J. Kwasa, R. Walker (Newcastle Upon Tyne, United Kingdom)
Challenges in Implementing Relevant Exercise Interventions in Mouse Models of Parkinson’s Disease

D. Grogan, H. Skelton, J. Rubiano, C. Gutekunst, R. Gross (Augusta, USA)
Changes in brain functional connectivity after cognitive behavioral therapy for anxiety in Parkinson’s disease: a longitudinal MRI study.

G. Carey, R. Lopes, A. Moonen, K. Dujardin, A. Leentjens (Lille, France)
Changes in the cerebellar activity during task based and resting state fMRI in Parkinson’s disease patients with mild cognitive impairment

J. Yang, G. Byrne, K. Mcmahon, D. Copland, J. O'Sullivan, N. Dissanayaka (Herston, Australia)
CHAPERONIC PROPENSITIES OF AFRICAN WALNUT AS A THERAPEUTIC TARGET IN MANGANESE-INDUCED PARKINSON-LIKE NEUROPATHOLOGY IN WISTAR RATS

O. Tokunbo, B. Enaibe, T. Abayomi (Osogbo, Nigeria)
Characterising the incidence of comorbidities, hospitalisations, and death in patients diagnosed with Huntington’s disease: A cohort study of linked Swedish National Registries (2002-2019)

H. Furby, S. Moore, A. Nordstroem, R. Houghton, D. Lambrelli, S. Graham, P. Svenningsson, A. Petersen (Welwyn Garden City, United Kingdom)
Characteristics and outcomes of Parkinson’s disease individuals hospitalized with COVID-19 in a New York City hospital system

L. Nwabuobi, C. Zhang, C. Henchcliffe, H. Shah, H. Sarva, A. Lee, H. Kamel (New York, USA)
Characteristics of daily exercise patterns in various stages of Parkinson’s disease

J. Song, JK. Mun, JH. Ahn, J. Youn, I. Choi, JW. Cho (Seoul, Republic of Korea)
Characteristics of the amyloid beta networks in Parkinson’s disease patients: a PPMI study

A. Mihascu, M. Valli, M. Diez-Cirarda, Y. Koshimori, J. Kim, A. Strafella (Toronto, Canada)
Characterization of a mouse model of PDE10A-related autosomal-dominant movement disorder.

N. Marotta, N. Mencacci, M. Pereira Luppi, R. Awatramani, D. Krainc (Chicago, USA)
CHARACTERIZATION OF LRP10 EXPRESSION IN LEWY BODY DISORDERS AND IPSC-DERIVED BRAIN CELLS

M. Grochowska, A. Carreras Mascaro, V. Boumeester, D. Natale, G. Breedveld, H. Geut, W. van Cappellen, A. Boon, A. Kievit, E. Sammler, P. Parchi, P. Cortelli, D. Alessi, W. V.D. Berg, V. Bonifati, W. Mandemakers (Rotterdam, Netherlands)
Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile-X Associated Tremor/Ataxia Syndrome

D. Abbasi, T. Nguyen, E. Robertson-Dick, E. Berry-Kravis, S. Cologna, D. Hall (Chicago, USA)
Characterizing Racial and Ethnic Diversity Among Enroll-HD Participants in the US and Canada

N. Dahodwala, V. Sung, P. Gonzalez-Alegre, E. Korner, A. Patel, J. Ko, J. Ta, J. Sanchez-Ramos (Philadelphia, USA)
Characterizing the temporal discrimination threshold in musician’s dystonia

F. Borngräber, M. Hoffmann, T. Paulus, J. Junker, T. Bäumer, E. Altenmüller, A. Kühn, A. Schmidt (Berlin, Germany)
Characterizing US Healthcare Delivery in Huntington’s Disease (HD)

L. Seeberger, J. Corey-Bloom, M. O'Brien, P. Chen, B. Griffin, D. Schlang, D. Slowiejko (Aurora, USA)
Childhood-Onset Hemidystonia: A Transportophaty related to SLC6A3 missense mutation

G. Prado-Miranda, K. Salinas-Barboza, JM. Altamirano, AA. Alvarado-Bolaños (Mexico City, Mexico)
Choreoathetosis in the setting of HHV-6 infection in an allogeneic transplant recipient

S. Mancone, C. Selvadurai, J. Baehring, A. Patel (New Haven, USA)
Chronic sensing of the subthalamic nucleus in Parkinson’s disease patients: preliminary observations

Y. Thenaisie, C. Palmisano, A. Canessa, E. Martin-Moraud, I. Isaias, F. Contarino (Lausanne, Switzerland)
Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results

A. Lang, A. Siderowf, E. Macklin, W. Poewe, D. Brooks, H. Fernandez, O. Rascol, N. Giladi, F. Stocchi, C. Tanner, R. Postuma, D. Simon, E. Tolosa, B. Mollenhauer, M. Byrne, K. Fraser, J. Xiao, I. Sapir, J. Inra, R. Hutchison, M. Yang, T. Fox (Toronto, Canada)
Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study

RM. Hutchison, K. Fraser, M. Yang, B. Hirschhorn, J. Xiao, D. Scott, B. Bedell, K. Evans, D. Graham, L. Martarello, J. Beaver, J. Cedarbaum, T. Fox, A. Siderowf, A. Lang (Cambridge, USA)
Classification of Advanced Parkinson’s Disease in OBSERVE-PD Patients Based on the MANAGE-PD Screening Tool

A. Fasano, V. Fung, K. Seppi, Z. Pirtosek, L. Bergmann, A. Alobaidi, K. Onuk (Toronto, Canada)
Classifying pain in dystonia: a way to improve pain outcome measure in dystonia.

C. Listik, E. Listik, J. Lapa, G. Santos, F. Do Vale, R. Cury, M. Teixeira, J. Limongi, H. Ferraz, E. Barbosa, D. de Andrade (São Paulo, Brazil)
CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform

E. Berkovich (Petch-Tikva, Israel)
Climb up! Head up! Effectiveness and feasibility of sport climbing in Parkinson’s disease

A. Langer, H. Zach, S. Hasenauer, A. Flotz, L. Gassner, R. Pokan, P. Dabnichki, L. Wizany, D. Roth, S. Zimmel, M. Treven, M. Schmoeger, U. Willinger, W. Maetzler (Wien, Austria)
Clinical and Economic Outcomes Associated with Dysphagia in Hospitalized Patients with Parkinson’s Disease

D. Di Luca, E. Mcarthur, A. Willis, R. Martino, C. Marras (Toronto, Canada)
Clinical and genetic analysis of psychosis in Parkinson’s disease

B. Radojević, N. Dragašević, A. Milovanović, V. Dobričić, M. Svetel, I. Petrović, M. Savić, I. Jančić, D. Stanisavljević, A. Marjanović, M. Branković, V. Kostić (Belgrade, Serbia)
Clinical and imaging features of idiopathic cerebellar ataxia with anti-cerebellar antibodies

A. Takekoshi, A. Kimura, N. Yoshikura, T. Shimohata (Gifu, Japan)
Clinical and transcranial sonography characteristics in benign phenotype of Parkinson’s disease.

A. Planas-Ballvé, N. Caballol, A. ávila (Barcelona, Spain)
Clinical characteristics and factors associated musculoskeletal pain in Parkinson’s disease: A retrospective study from two centers in China

J. Li, B. Zhu, Z. Gu, H. Zhang, S. Liu, S. Mei, S. Ji, H. Chen, E. Xu, P. Chan (Hefei, China)
Clinical Characteristics of Essential Tremor in Tunisia

M. Akkari, M. Zouari (Tunis, Tunisia)
CLINICAL CHARACTERISTICS OF PARKINSON’S DISEASE WITH PROBABLE RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER

S. Marisdina, A. Afriani, M. Mukhlisa, S. Handayani, O. Tambun, R. Nindela, Y. Diansari (Palembang, Indonesia)
Clinical Correlates of Functional Motor Disorders in childhood and adolescence: an emerging diagnostic and clinical challenge.

V. Baglioni, S. Galosi, S. Cesario, F. Gigliotti, C. Di Maggio, F. Di Santo, V. Leuzzi (Rome, Italy)
Clinical correlates of Parkinson’s disease metabolic pattern: not only a diagnostic tool

G. Martí-Andrés, R. Valentí, E. Prieto, M. Riverol, MR. Luquin, J. Arbizu (Pamplona, Spain)
Clinical correlates of sleep disturbances in children with Tourette syndrome

L. Keenan, J. Bramham, M. Downes (Dublin, Ireland)
Clinical correlates of visual hallucinations in Parkinson’s disease

G. Mandic Stojmenovic, T. Stojkovic, E. Stefanova, V. Markovic, I. Stankovic Tutus, I. Petrovic, N. Dragasevic Miskovic, M. Svetel, V. Kostic (Belgrade, Serbia)
Clinical epidemiology of movement disorders in Douala General Hospital, Cameroon: A two years retrospective study

D. Gams Massi, AM. Magnerou, G. Tchumno Mayoue, EA. Babe, NY. Mapoure (Douala, Cameroon)
Clinical Features Associated with Dysautonomia in Prodromal Parkinson’s Disease

C. Miller-Patterson, J. Hsu, J. Morley, A. Siderowf, A. Willis (Philadelphia, USA)
Clinical heterogeneity of DYT-KMT2B mutation in a family with monozygotic twins

O. Mcwilliam, C. Fagerberg, M. Larsen, D. Kondiziella, I. Havsteen, A. Løkkegaard (Copenhagen N, Denmark)
Clinical Outcomes in Parkinson’s with COVID 19 during the’ first wave’ in West Berkshire, United Kingdom (UK)

M. Khwaja, A. Chatterjee, N. Butt, N. Virgincar, M. Todd, T. Nanayakkara, G. Pun (Reading, United Kingdom)
Clinical phenotype and biomarkers in sporadic degenerative ataxia: longitudinal data from the SPORTAX registry

D. önder, C. Wilke, J. Faber, T. Schaprian, I. Giordano, M. Grobe-Einsler, L. Schöls, S. Vielhaber, J. Machts, C. Kamm, A. Dudesek, T. Klopstock, C. Stendel, D. Timmann-Braun, S. Boesch, A. Eigentler, B. van Dewarrenburg, J. van Gaalen, C. Tallaksen, I. Wedding, A. Filla, G. Silvestri, M. Masciullo, C. Ganos, J. Kang, D. Sarah, M. Synofzik, T. Klockgether (Bonn, Germany)
Clinical predictors of impulsive and compulsive behavior after subthalamic stimulation in Parkinson’s disease

A. Sauerbier, P. Loehrer, S. Jost, S. Heil, J. Petry-Schmelzer, J. Herberg, P. Bachon, S. Aloui, A. Gronostay, L. Klingelhoefer, J. Baldermann, D. Huys, C. Nimsky, M. Barbe, G. Fink, P. Martinez-Martin, K. Chaudhuri, V. Visser-Vandewalle, L. Timmermann, D. Weintraub, H. Dafsari (Cologne, Germany)
Clinical presentation of coexistence of Spinocerebellar ataxia (SCA14) gene duplication variant in association with Spinocerebellar Ataxia (SCA8) gene mutation in a same patient.

A. Ahmed (Winter Park, USA)
Clinical presentation of Wilson’s disease in pediatric and adult patients: A systematic review

A. Rochel-Pérez, K. Santos-Zaldivar, O. Cuevas-Koh, M. Azuela-Morales, N. Méndez-Domínguez (Mérida, Mexico)
Clinical profile and treatment outcomes of inherited hypermanganesemia among 27 Indian children: A retrospective multi-centric study

D. Garg, S. Yoganathan, A. Saini, N. Sankhyan, U. Kalane, K. Srivastava, A. Bothre, D. Panigrahi, M. Kamate, M. Juneja, V. Udani, S. Sharma (Delhi, India)
Clinical variants of PSP: phenotypical convergence and its relationship with the brain glucose metabolism

G. Martí-Andrés, D. Vállez-García, E. Prieto, L. van Bommel, S. Meles, R. Valentí, R. Kogan, V. Gurvits, M. Riverol, MR. Luquin, KL. Leenders, J. Arbizu (Pamplona, Spain)
Close relationship between CSF lipidomic alterations and cognitive decline in Parkinson’s disease.

Y. Mizutani, S. Shima, A. Ueda, M. Ito, H. Watanabe (Toyoake, Japan)
Closing the gap: How to record valuable data for movement disorders using FHIR

J. Mecklenburg, G. Wenzel, A. Kreichgauer, C. Friedow, AA. Kühn (Berlin, Germany)
Closing the Loop on Essential Tremor Using Thalamic and Cortical Control Signals

B. Parks, A. Gunduz, K. Foote (Gainesvile, USA)
Cluster headache associated with secondary unilateral blepharospasm : A Case Report

P. Dugani, A. Mehta, P. R, M. Javali, P. Acharya, R. Srinivasa (Bengaluru, India)
Co-designing a meaningful, humane and personalized eHealth platform (eCARE-PD) for people living with Parkinson’s Disease

S. Grosjean, JL. Ciocca, E. Poitras, A. Gauthier-Beaupré, D. Côté, D. Grimes, T. Mestre (Ottawa, Canada)
Coffee, smoking and aspirin are associated with age at onset and clinical severity in idiopathic Parkinson’s disease

C. Gabbert, I. König, T. Lüth, M. Kasten, A. Grünewald, C. Klein, J. Trinh (Lübeck, Germany)
Cognition-related functional topographies in Parkinson’s disease: Localized loss of the ventral default mode network

K. Schindlbeck, A. Vo, P. Mattis, K. Villringer, F. Marzinzik, J. Fiebach, D. Eidelberg (Manhasset, USA)
Cognitive assessment in a Greek cohort of Multiple System Atrophy patients.

A. Bougea, C. Koros, A-M. Simitsi, N. Papagiannakis, E. Efthymiopoulou, I. Pachi, C. Chrysovitsanou, R. Antonelou, V. Constantinides, E. Kapaki, L. Stefanis (Athens, Greece)
Cognitive assessment of Parkinson’s Disease patients in a Northeast Brazilian population: Current Challenges

J. Bonfadini, D. Lima, A. Carneiro, J. Luna, A. Damasceno, P. Braga-Neto (Fortaleza, Brazil)
Cognitive complaints, anxiety, depression and reporting of pain in Parkinson’s Disease in a multi-ethnic population: Dissimilarities between White and Non-White patients

K. Rukavina, L. Batzu, M. Krbot Skoric, J. Staunton, A. Sauerbier, J. Ocloo, O. Awogbemelia, D. Trived, A. Rizos, K. Ray Chaudhuri (London, United Kingdom)
Cognitive Diagnostics for Parkinson’s Disease: A Novel Digitized Approach Using Non-Motor Symptoms

A. Murrar, M. Abu Snineh, M. Herzallah (Jerusalemp, State of Palestine)
Cognitive Impairment in Parkinson’s disease Patients: a Descriptive Study

R. Nindela, A. Kurniawan, Y. Harun, S. Marisdina, I. Irfannuddin (Palembang, Indonesia)
Cognitive impairment in patients with Alzheimer’s disease and Parkinson’s disease

O. Chyniak (Sumy, Ukraine)
Cognitive profiling in a cohort of Primary Familial Brain Calcification (PFBC) patients

M. Garon, M. Carecchio, L. Weis, F. Pistonesi, M. Mainardi, G. Bonato, L. Salviati, A. Antonini, R. Biundo (Padova, Italy)
Cognitive reserve in non-demented patients with Parkinson’s disease might protect against amyloid burden effect on cognition

B. Fernández-Rodríguez, R. Rodríguez-Rojas, P. Guida, C. Trompeta, D. Mata-Marín, I. Obeso-Martín, L. Vela, L. García-Cañamaque, JA. Obeso, C. Gasca-Salas (Móstoles, Spain)
Cognitive-affective syndrome related to cerebellar hypometabolism secondary to Covid-19 infection : a case report

S. Potel, M. Merceur, P. Méneret, S. Butet, P. Guillemot, G. Silvestre-Beccarel, I. Bonan, F. Le Jeune, M. Vérin (Rennes, France)
Cognitive-driven ADL impairment as a predictor for PDD

I. Liepelt-Scarfone, M. Bode, K. Brockmann, T. Gasser, K. Michaelis, S. Nussbaum, HC. Nuerk, C. Schulte, W. Maetzler, M. Zimmermann, D. Berg, S. Becker (Tübingen, Germany)
Combined dystonia in a patient carrying a novel ATL1 gene variant.

M. Gea, K. Beyer, F. Nuñez, L. Ispierto, R. álvarez, G. Lucente, D. Vilas (Badalona, Spain)
Combined effects of GBA mutations and STN-DBS negatively impact cognition in Parkinson’s disease

G. Pal, G. Mangone, E. Hill, V. Lythe, D. Ehrlich, R. Saunders-Pullman, V. Shanker, S. Bressman, R. Alcalay, P. Garcia, K. Marder, J. Aasly, M. Mouradian, B. Ouyang, Y. Liu, S. Ruehl, M. Rosenbaum, S. Anderson, B. Bernard, D. Hall, S. Sani, L. Verhagen, R. Debie, T. Foltynie, J. Corvol, C. Goetz (New Brunswick, USA)
Combined Plantar Stimulations Using a Novel Parkinson Shoe benefit Parkinson’s Disease Patients with Unresponsive Freezing of Gait

W. Phuenpathom, P. Panyakaew, S. Fungtammasan, P. Vateekul, R. Bhidayasiri (Bangkok, Thailand)
Community-Based Multidisciplinary Program for People with Parkinson Disease: A 2-year comparison

S. Parveen, T. Passmore, B. Brickell, S. Jackson (Stillwater, USA)
Comorbid Moyamoya Disease and Parkinson’s disease: A case series

D. Yoo (Seoul, Republic of Korea)
Comparability of frame systems for the implantation of DBS electrodes in Parkinson’s disease

G. Gonzalez-Escamilla, M. Glaser, R. Ploen, M. Bange, L. Serrano, M. Muthuraman, S. Groppa (Mainz, Germany)
Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation

T. Tsuboi, J. Wong, R. Eisinger, L. Okromelidze, M. Burns, A. Ramirez-Zamora, L. Almeida, A. Wagle Shukla, K. Foote, M. Okun, S. Grewal, M. Katsuno, E. Middlebrooks (Gainesville, USA)
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients With Advanced Parkinson’s Disease

M. Soileau, F. Pagan, A. Fasano, R. Rodriguez, N. Gupta, A. Xi, M. Kambhampati, A. Murunga, C. Teigland, P. Kandukuri, Y. Jalundhwala, O. Ladhani, M. Siddiqui (Georgetown, USA)
Comparative Measurement of Balance between Parkinson Disease and Spinocerebellar Ataxia – A Dynamic Posturography Study

V. Selvaganapathy, T. James, M. Philip, N. Kamble, A. Bhattacharya, A. Stezin, P. Dhargave, P. Pal, V. Muralidharan, M. P S, P. Kishore (Bangalore, India)
Comparative score on the MDS-UPDRS scale I, II and IV in patients with Parkinson disease with and without cardiovascular risk factors.

H. Gonzalez-Usigli, A. Gonzalez-Vazquez, J. Garcia-Rivera, O. Padila-Delatorre, A. Leon-Gil, H. Gonzalez-Rodriguez (Guadalajara, Mexico)
Comparison and analysis of pupillometer parameters between patients with drug naive Parkinson’s disease and controls

S. You, J. Yoo (Daegu, Republic of Korea)
Comparison of Activa PC to Percepttm impedance assessment across device exchanges

E. Hargreaves, D. Caputo, D. Schneider, R. Dipaola, J. Chen, Y. Fernandez, S. Danish (New Brunswick, USA)
Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3

J. Chan, N. Hanan, J. Lowell, M. Kostrzebski, D. Penz, C. Tarolli, T. Mestre, A. Lutz, C. Lungu, C. Coffey, D. Oakes, M. Schwarzschild, T. Simuni, E. Macklin (Boston, USA)
Comparison of correlations of structural magnetic resonance imaging measures with smartphone-based active tests and clinical tests in Huntington’s disease

J. Rennig, D. Hawellek, J. Dorn, F. Lipsmeier, S. Holiga, C. Simillion, S. Schobel, M. Lindemann (Basel, Switzerland)
COMPARISON OF ELECTROPHYSIOLOGIC AND ULTRASOUND GUIDANCE FOR ONABOTULINUM TOXIN-A INJECTIONS IN FOCAL UPPER EXTREMITY SPASTICITY AND DYSTONIA

C. Lungu, A. Nmashie, MC. George, T. Wu, S. Shin, B. Karp, E. Considine, W. Tse, S. Frucht, C. Wu, V. Koo, G. Norato, K. Alter, M. Hallet, DM. Simpson ()
COMPARISON OF FREQUENCY, CLINICAL PROFILE AND ETIOLOGIES OF PARKINSONISM IN 2008 AND 10 YEARS LATER AT THE NEUROLOGY DEPARTMENT OF BEFELATANANA UNIVERSITY TEACHING HOSPITAL, ANTANANARIVO, MADAGASCAR

NF. Rasaholiarison, M. Ratsimandresy, JL. Rakotomanana, A. Tehindrazanarivelo (Fianarantsoa, Madagascar)
Comparison of gastrointestinal transit times in typical and erratic levodopa-responders in patients with Parkinson’s disease.

D. Safarpour, B. Brumbach, M. Arena, J. Quinn, J. Nutt, R. Pfeiffer (Portalnd, USA)
Comparison of pre – and post – clinical outcomes after COVID-19 lockdown in people with Parkinson’s in Portugal

C. Godinho, D. Tavares, J. Dean, J. Domingos (Sintra, Portugal)
Comparison of video-instructed and operator-instructed markerless motion analysis with clinical rating-scales in patients with Parkinson’s Disease

J. Bendig, H. Röhling, J. Leidig, A. Spanz, A. Frank, K. Loewenbrück, K. Otte, B. Falkenburger (Dresden, Germany)
Comparisons Between Parkinson’s Disease Patients and At-Risk Individuals: Can Olfactory Deficits and Cognitive Measures Serve as Preclinical Markers?

L. Pimer, J. Fisk, M. Khan, R. Mckelvey, H. Robertson, T. Rolheiser, K. Schoffer, K. Good (Halifax, Canada)
Compensation strategies for gait impairment in Parkinson’s disease: a survey among 4,324 patients

A. Tosserams, L. Wit, I. Sturkenboom, M. Nijkrake, B. Bloem, J. Nonnekes (Nijmegen, Netherlands)
Compensatory functional mechanisms of response inhibition in Parkinson’s Disease with impulse control disorders

T. Esteban-Peñalba, P. Paz-Alonso, I. Navalpotro-Gomez, M. Rodriguez-Oroz (Donostia, Spain)
Complex Pediatric Tone and Movement Disorder Clinic: A Model for Multi-disciplinary Care in Qatar.

K A. Mohamed, I. Pople, K. Al-Kharazi, K. Southwood, C. Le Bars, A. Creighton-Griffiths, B S. Patel, E. Makhoul, T. Collier, L. Thornton (Doha, Qatar)
Comprehensive analysis of non-motor symptoms and their association with quality of life in writer’s cramp

LY. Zhang, YB. Hou, J. Yang, B. Cao, HF. Shang (Chengdu, China)
Comprehensive analysis of PRKN in a large Parkinson’s Disease cohort identifies causative mutations and validates population scale screening by microarray

W. Zhu, X. Huang, E. Yoon, S. Bandres-Ciga, C. Blauwendraat, J. Cade, B. Wu, J. Brooks, J. Gibbs, D. Hernandez, D. Ehrlich, A. Singleton, D. Narendra (Bethesda, USA)
Conception of a sensor- and home-based measurement of camptocormia

R. Wolke, K. Naderi Beni, H. Wolframm, R. Rieger, N. Margraf (Kiel, Germany)
Conceptualization of Gait Assessment Model Using Auditory and Visual Cues

O. Dada (Ibadan, Nigeria)
Connectomic Analysis of SNc and VTA Projections to the Striatum and Cortex

N. Handfield-Jones, A. Owen, A. Khan, P. Macdonald (London, Canada)
Constipation in Parkinson’s disease: Clinical and Neurosonographic Study

R. Soliman, N. Kishk, M. Oraby, A. Alsayyad, M. Abdelsalam, M. Abosrea (Cairo, Egypt)
Correction of gait pattern in Parkinson’s disease

S. Ismailova, S. Prokopenko (Krasnoyarsk, Russian Federation)
Correlating LRRK2 activation status in peripheral blood to urine BMPs in monogenic and idiopathic Parkinson’s disease

S. Gomes, A. Garrido, F. Tonelli, E. Tolosa, M. Marti, D. Anderson, N. Pratuseviciute, F. Hsieh, T. Bruecke, T. Koenig, C. Hotzy, J. Ruiz-Martínez, A. Bergareche-Yarza, E. Mondragón Rezola, A. Vinagre Aragón, I. Croitoru, A. Gorostidi Pagola, L. Paternain Markinez, F. Valldeoriola, K. Merchant, S. Padmanabhan, A. Zimprich, D. Alessi, E. Sammler (Dundee, United Kingdom)
Correlation between sleep quality, risk of falls and balance in elderly with Parkinson’s disease

P. Silva, L. Pereira, M. Terra, H. Araujo, N. Barboza, M. Bueno, S. Smaili (Londrina, Brazil)
Cortical microstructural alterations are more sensitive than morphology changes to cortical degeneration in Parkinson’s disease with mild cognitive impairment

X. Bai, T. Guo, X. Guan, C. Zhou, J. Wu, M. Zhang (Hangzhou, China)
Cost of Predictive Genetic Testing for Huntington’s Disease at Centers of Excellence in the US

M. Massey, T. Orem, V. Sung (Birmingham, USA)
Could Gender have an effect on Clinical and Transcranial Parenchymal Ultrasound Findings in Parkinson’s disease Patients?

R. Soliman, N. Kishk, M. Oraby, A. Alsayyad, M. Abdel Salam, M. Abo Srea (Cairo, Egypt)
COVID-19 and Parkinson’s disease care: Challenges and opportunities for social work practice

J. Shurer, N. Browner, L. Zerden, T. Guan, L. Kreitzer, E. Book (Chapel Hill, USA)
Covid-19 associated Opsoclonus-Myoclonus Syndrome with encephalopathy

A. Tageldin, L. White, M. Ellul, V. Bharambe, B. Michael, M. Bonello, S. Alusi (Southport, United Kingdom)
COVID-19 PANDEMIC: SYMPTOMS PERCEPTIONS FROM PARKINSON’S DISEASE PATIENTS

A. Braga, L. Brito, F. Rolim, P. Andrade, A. Marinho, A. Moura, H. Freitas, I. Nobrega, I. Dantas, F. Carvalho (Fortaleza, Brazil)
CSF MicroRNA Analysis Reveals Angiogenesis And Autophagy Defects In Parkinson’s DiseasePatients

C. Moussa, Y. Torres-Yaghi, F. Pagan (Washington, USA)
Cumulative Real-World Experience with Deutetrabenazine for Huntington’s Disease Chorea at a Single Center of Excellence in the US

K. Curtis, B. Denson, V. Sung (Birmingham, USA)
Cuneiform Nucleus Deep Brain Stimulation for Freezing of Gait in Parkinson’s disease. Initial clinical report.

C. Luca, S. Chang, I. Cajigas, J. Guest, I. Haq, B. Noga, J. Jagid (Miami, USA)
Current perspectives on the management of cervical dystonia among global clinicians

H. Jinnah, H. Ferraz, S. Standal, P. Fattahi, A. Zuzek, N. Alibhai, K. Merath (Atlanta, USA)
CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson’s disease (PD): a meta-analysis

M. Saint-Hilaire, A. Corbin, P. Zhao, D. Kegler-Ebo (Boston, USA)
CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)

P. Lewitt, P. Zhao, A. Corbin, D. Kegler-Ebo, B. Blank (West Bloomfield, USA)